[1] Azevedo MM, Lisboa C, Cobrado L, et al. Hard-to-heal wounds, biofilm and wound healing: an intricate interrelationship. Br J Nurs, 2020; 29, S6−13.
[2] Ahmad E, Lim S, Lamptey R, et al. Type 2 diabetes. Lancet, 2022; 400, 1803−20. doi:  10.1016/S0140-6736(22)01655-5
[3] Li SX, Mohamedi AH, Senkowsky J, et al. Imaging in chronic wound diagnostics. Adv Wound Care (New Rochelle), 2020; 9, 245−63. doi:  10.1089/wound.2019.0967
[4] Beegle J, Lakatos K, Kalomoiris S, et al. Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. Stem Cells, 2015; 33, 1818−28. doi:  10.1002/stem.1976
[5] Zubair M, Ahmad J. Role of growth factors and cytokines in diabetic foot ulcer healing: A detailed review. Rev Endocr Metab Disord, 2019; 20, 207−17. doi:  10.1007/s11154-019-09492-1
[6] Fernández-Santos ME, Garcia-Arranz M, Andreu EJ, et al. Optimization of mesenchymal stromal cell (MSC) manufacturing processes for a better therapeutic outcome. Front Immunol, 2022; 13, 918565. doi:  10.3389/fimmu.2022.918565
[7] Yang YM, Lee EH, Yang Z. Hypoxia-conditioned mesenchymal stem cells in tissue regeneration application. Tissue Eng Part B: Rev, 2022; 28, 966−77. doi:  10.1089/ten.teb.2021.0145
[8] Ishiuchi N, Nakashima A, Doi S, et al. Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats. Stem Cell Res Ther, 2020; 11, 130.
[9] Yusoff FM, Nakashima A, Kawano KI, et al. Implantation of hypoxia-induced mesenchymal stem cell advances therapeutic angiogenesis. Stem Cells Int, 2022; 2022, 6795274.
[10] Tan LS, Chen JT, Lim LY, et al. Manufacturing clinical-grade human induced pluripotent stem cell-derived beta cells for diabetes treatment. Cell Prolif, 2022; 55, e13232.